Related Experiment Video
Updated: Mar 26, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
23.4K
Antineoplastic agents and thrombotic microangiopathy.
Gwenalyn Garcia1, Jean Paul Atallah1
1Department of Medicine, Division of Hematology/Oncology, Staten Island University Hospital, Staten Island, NY, USA.
Summary
Thrombotic microangiopathy is a rare side effect of cancer treatments like chemotherapy and targeted therapies. Understanding this adverse event is crucial for managing cancer therapy safely.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Thrombotic microangiopathy (TMA) is a serious adverse effect linked to various antineoplastic drugs.
- This condition has been reported with traditional chemotherapy agents (e.g., mitomycin C, gemcitabine) and newer targeted therapies, including vascular endothelial growth factor inhibitors.
Purpose of the Study:
- To review the occurrence of thrombotic microangiopathy (TMA) associated with antineoplastic agents.
- To discuss the implications of TMA in the context of current cancer treatment strategies.
Main Methods:
- Literature review of reported cases and studies on antineoplastic agent-induced TMA.
- Analysis of drug classes associated with TMA.
- Synthesis of clinical implications for cancer therapy management.
Main Results:
- Thrombotic microangiopathy (TMA) is an uncommon but recognized complication of diverse antineoplastic drugs.
- Both conventional chemotherapy and targeted therapies can induce TMA.
- Specific examples include mitomycin C, gemcitabine, and VEGF inhibitors.
Conclusions:
- Awareness of thrombotic microangiopathy (TMA) is essential for oncologists and hematologists.
- Monitoring for TMA is critical during treatment with certain antineoplastic agents.
- Managing TMA may require dose modification or discontinuation of cancer therapy.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:29Venous Thrombosis III: Interprofessional Care
460
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
01:10Drugs that Destabilize Microtubules
4.3K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:15Drugs that Stabilize Microtubules
2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K